Join
Live feed
·
PRReleasevia Quantisnow
PolyPid Ltd. logo

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

ByQuantisnow·Wall Street's wire, on your screen.
PYPD· PolyPid Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PYPD (PolyPid Ltd.) and more on Quantisnow.